Adezmapimod

Description: Adezmapimod (SB 203580) is a selective, ATP-competitive p38 MAPK inhibitor (IC50=0.3-0.5 µM) that activates autophagy and mitochondrial autophagy, with more than 100-fold higher selectivity over PKB, LCK, and GSK-3beta. Target: Autophagy, p38 MAPK, Mitophagy. Smiles: FC1=CC=C(C2=C(N=C(N2)C3=CC=C(S(C)=O)C=C3)C=4C=CN=CC4)C=C1. References: Henklova P, et al. SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. Eur J Pharmacol. 2008 Sep 28,593(1-3):16-23.